Indivior Pharmaceuticals, Inc.
As of Oct 22, 2026, Indivior Pharmaceuticals is in Stage 4, the downtrend phase, now in its first week (since Oct 22, 2026). It closed at $35.33, 15.5% below its 52-week high and below its 200-day average, which is falling.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and r… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is INDV early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
INDV among Drug Manufacturers - Specialty & Generic14th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …14 | INDV | Stage 4 · wk 1 | 85 | −1.6% |
Indivior Pharmaceuticals: quick answers
What stage is Indivior Pharmaceuticals in?
As of Oct 22, 2026, Indivior Pharmaceuticals (INDV) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 22, 2026 and is in its first week there. What the four stages mean
Is Indivior Pharmaceuticals in an uptrend?
No. Indivior Pharmaceuticals is in a Stage 4 downtrend. It trades 0.9% below its 200-day average, which is falling.
How far is Indivior Pharmaceuticals from its 52-week high?
Indivior Pharmaceuticals closed at $35.33 on Oct 22, 2026, 15.5% below its 52-week high of $41.83. Its 52-week low is $24.78.
How has Indivior Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Indivior Pharmaceuticals is up 46.7% over the past year and down 1.1% so far in 2026.
Which sector and industry is Indivior Pharmaceuticals in?
Indivior Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.